These inhibitors could potentially be used in the management of various cancers associated with TrkA activation, such as lung, breast, cervix, thyroid, and oral cavity cancers (Lagadec et al., 2009; Sasahira et al., 2013; Faulkner et al., 2018; Gao et al., 2018; Faulkner et al., 2020). The gene discussed is NTRK1; the disease is cancer.